SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 12, 2002
SALIX PHARMACEUTICALS, LTD.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
- --------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
000-23265 94-3267443
- ------------------------------------ ------------------------------------
(Commission file Number) (IRS Employer ID Number)
8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (919) 862-1000
--------------
Item 5. Other Events and Regulation FD Disclosure
On February 12, 2002, Salix Pharmaceuticals, Ltd. filed a registration
statement on Form S-3 related to the proposed public offering of 4,000,000
shares of its common stock, par value $0.001.
A copy of the preliminary prospectus included within the registration
statement is attached as an exhibit.
Item 7. Financial Statements and Exhibits
(c) Exhibits
2.1* Certificate of Domestication
3.1* Certificate of Incorporation
23.1 Consent of Independent Auditors
99.1 Preliminary Prospectus dated February 12, 2002
99.2* Loan and Security Agreement dated March 30, 2001, First
Amendment to Loan and Security Agreement dated October 4, 2001
and First Waiver to Loan and Security Agreement dated November
12, 2001, between General Electric Capital Corporation and
Salix Pharmaceuticals, Ltd.
---------------------------------
* Incorporated by reference to exhibits included in the Registrant's
Registration Statement on Form S-3 filed with the Securities and
Exchange Commission on February 12, 2002.
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SALIX PHARMACEUTICALS, LTD.
Date: February 12, 2002 By: /s/ Adam C. Derbyshire
-------------------------------------
Adam C. Derbyshire
Vice President and
Chief Financial Officer